Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

$7.2 Billion Blockbuster Deal Puts Medical Cannabis Sector In The Spotlight

By Investing.com (Brenda O'Farrell/Investing.com)Stock MarketsFeb 09, 2021 06:28AM ET
www.investing.com/analysis/72-billion-blockbuster-deal-puts-medical-cannabis-sector-in-the-spotlight-200559457
$7.2 Billion Blockbuster Deal Puts Medical Cannabis Sector In The Spotlight
By Investing.com (Brenda O'Farrell/Investing.com)   |  Feb 09, 2021 06:28AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

The latest deal creating a buzz in the cannabis industry is the US$7.2-billion takeover of GW Pharma (NASDAQ:GWPH) by a little-known, Ireland-based company—Jazz Pharmaceuticals (NASDAQ:JAZZ).

The acquisition announced last week is the biggest takeover in the marijuana industry, and could have wide implications for the growing cannabinoid-based medication sector.

JAZZ Daily
JAZZ Daily

GW Pharma is the UK-based company that was the first firm to market a drug that used purified CBD—the non-psychoactive component of cannabis—that is now used to treat children who suffer from severe epilepsy. The drug, Epidiolex, was approved by the U.S. Food and Drug Administration in 2018. The company is also in testing trials for other cannabis-based treatments for multiple sclerosis, autism and schizophrenia.

Jazz Pharmaceuticals markets a number of cancer drugs as well as a leading treatment for narcolepsy, a chronic sleep disorder that prompt severe bouts of daytime drowsiness.

Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals said:

"Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business. We are excited to add GW's industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities."

The deal points to a broadening of the medical uses for cannabis within the health-care field, setting the stage for what many in the industry view as a growing market for cannabis-based pharmaceutical products which have gained traction with regulators, especially in the European markets.

The mere size of the deal to acquire GW Pharma just about dwarfs another recent merger in the industry, that of the US$3.8-billion agreement announced in December that saw Tilray (NASDAQ:TLRY) and Aphria (NASDAQ:APHA), two of the biggest names in the cannabis industry, merge.

Aurora Reports Earnings Thursday

Following on the heels of yesterday’s earnings results reported by Canopy Growth (NASDAQ:CGC) before the opening bell, the next big quarterly filing in the cannabis sector comes Thursday, when Aurora Cannabis (NYSE:ACB) unveils its Q2 results after the market close.

Based on reported analyst forecasts, the headline will be an expected earnings per share loss of $0.19, which is not what many investors would be hoping for, but better than the $2.16 EPS loss for the same quarter in the previous fiscal year.

Shares of Aurora closed yesterday with a 16.2% gain on the day. They have more than doubled in the last three months, but are still down just over 27% on the year.

In January, the Edmonton-based cannabis grower it was laying off staff after signing a deal with an external sales broker, which took over much of the firm’s sales representations. Aurora did not disclose how many employees it was cutting. In 2020, it also cut about 1,000 positions when it announced it was streamlining its operations and closing some growing facilities.

$7.2 Billion Blockbuster Deal Puts Medical Cannabis Sector In The Spotlight
 

Related Articles

$7.2 Billion Blockbuster Deal Puts Medical Cannabis Sector In The Spotlight

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (5)
Md Sablu
Md Sablu Feb 10, 2021 12:36PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sablu
Ray Delara
Ray Delara Feb 09, 2021 1:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Informative!
Md Sablu
Md Sablu Feb 09, 2021 1:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sablu
reza youn
reza youn Feb 09, 2021 12:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thank you for the information you gave us
Yoany Romeu
Yoany Romeu Feb 09, 2021 12:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i like this
Mo'men Mamdouh
Mo'men Mamdouh Feb 09, 2021 12:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Zynerba will skyrocket soon
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email